Efficacy and safety of a fourth dose of the COVID-19 vaccine in kidney transplant recipients: A systematic review and meta-analysis

作者：Kuniduzi, Yasen; Chen, Bo; Zeng, Jingjing; Sun, Xiaosong; Chen, Tao; Qian, Xiaoyuan; Wang, Jiange; Liang, Fuchao; Abuduxukuer, Rukeya; Yusufu, Maierhaba; Xu, Shaoyong^*; Zhang, Xuejun^*

来源：Transplant Immunology, 2023, 79: 101864.

DOI：10.1016/j.trim.2023.101864

• COVID-19
• Fourth vaccine
• Second booster vaccine
• Kidney transplantation
• Systematic review

Background: Kidney transplant recipients (KTRs) who become infected with SARS-CoV-2 are at greater risk of serious illness and death than the general population. To date, the efficacy and safety of the fourth dose of the COVID-19 vaccine in KTRs have not been systematically discussed.Methods: This systematic review and meta-analysis included articles from PubMed, Embase, the Cochrane Li-brary, Web of Science, China National Knowledge Infrastructure, and Wanfang Med Online published before May 15, 2022. Studies evaluating the efficacy and safety of a fourth dose of the COVID-19 vaccine in kidney transplant recipients were selected.Results: Nine studies were included in the meta-analysis, with a total of 727 KTRs. The overall pooled seropos-itivity rate after the fourth COVID-19 vaccine was 60% (95% CI, 49%-71%, I2 = 87.83%, p > 0.01). The pooled proportion of KTRs seronegative after the third dose that transitioned to seropositivity after the fourth dose was 30% (95% CI, 15%-48%, I2 = 94.98%, p < 0.01).Conclusions: The fourth dose of the COVID-19 vaccine was well tolerated in KTRs with no serious adverse effects. Some KTRs showed a reduced response even after receiving the fourth vaccine dose. Overall, the fourth vaccine dose effectively improved seropositivity in KTRs, as recommended by the World Health Organization for the general population.